GNPX News and Press, Genprex Inc. From 06/07/21

In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in Noble Capital Markets’ Virtual Roadshow Series, presented by Channelchek on May 20, 2021. T...

Investor presentation to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company fo...

Viewership of the 139 Channelchek videos released on Channelchek in 2020 was (and still are) through the roof. Looking back, this makes sense. After all, 2020 brought many new investors to the financial markets - Channelchek’s purpose is to provide information to investors at all levels...

Genprex CEO, Rodney Varner, tells Proactive its collaborators have presented positive preclinical data for the combination of REQORSA in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC), as well as for REQORSA in combination with targete...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity Emerging Growth...

Investor presentations to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company f...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center in Houston, Texas, t...

Genprex ([[GNPX]] +2.5%) announces that it has in-licensed additional gene therapy technologies for the treatment of lung cancer.The company and a major cancer research center in Houston, Texas has entered into an amendment to their May 2020 License Agreement enabling...

Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise Newly licensed technologies include use of Genprex’s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be resp...